Ranson MR - Search Results

1

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cross DA, et al. Among authors: ranson mr. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3. Cancer Discov. 2014. PMID: 24893891 Free PMC article.

2

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. Jänne PA, et al. N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817. N Engl J Med. 2015. PMID: 25923549 Free article. Clinical Trial.

3

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.

Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA. Planchard D, et al. Cancer Chemother Pharmacol. 2016 Apr;77(4):767-76. doi: 10.1007/s00280-016-2992-z. Epub 2016 Feb 22. Cancer Chemother Pharmacol. 2016. PMID: 26902828

4

EGFR T790M mutation testing within the osimertinib AURA Phase I study.

Dearden S, Brown H, Jenkins S, Thress KS, Cantarini M, Cole R, Ranson M, Jänne PA. Dearden S, et al. Lung Cancer. 2017 Jul;109:9-13. doi: 10.1016/j.lungcan.2017.04.011. Epub 2017 Apr 19. Lung Cancer. 2017. PMID: 28577957 Clinical Trial.

5

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A. Board RE, et al. Br J Cancer. 2009 Nov 17;101(10):1724-30. doi: 10.1038/sj.bjc.6605371. Epub 2009 Oct 27. Br J Cancer. 2009. PMID: 19861964 Free PMC article. Clinical Trial.

6

Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.

Aung KL, Donald E, Ellison G, Bujac S, Fletcher L, Cantarini M, Brady G, Orr M, Clack G, Ranson M, Dive C, Hughes A. Aung KL, et al. J Mol Diagn. 2014 May;16(3):343-9. doi: 10.1016/j.jmoldx.2013.12.004. Epub 2014 Mar 12. J Mol Diagn. 2014. PMID: 24631158 Free article.

7

Epidermal growth factor receptor tyrosine kinase inhibitors.

Ranson M. Ranson M. Br J Cancer. 2004 Jun 14;90(12):2250-5. doi: 10.1038/sj.bjc.6601873. Br J Cancer. 2004. PMID: 15150574 Free PMC article. Review.

8

Where next for gefitinib in patients with lung cancer?

Blackhall F, Ranson M, Thatcher N. Blackhall F, et al. Lancet Oncol. 2006 Jun;7(6):499-507. doi: 10.1016/S1470-2045(06)70725-2. Lancet Oncol. 2006. PMID: 16750500 Review.

9

ZD1839 (Iressa): for more than just non-small cell lung cancer.

Ranson M. Ranson M. Oncologist. 2002;7 Suppl 4:16-24. doi: 10.1634/theoncologist.7-suppl_4-16. Oncologist. 2002. PMID: 12202784 Free article. Review.

10

Phase II study of oral topotecan in advanced non-small cell lung cancer.

White SC, Cheeseman S, Thatcher N, Anderson H, Carrington B, Hearn S, Ross G, Ranson M. White SC, et al. Clin Cancer Res. 2000 Mar;6(3):868-73. Clin Cancer Res. 2000. PMID: 10741709 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters